Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -343K | 0 | -446K | -440K | -267K |
| Operating Income | -15M | -32M | -41M | -25M | -7M |
| EBITDA | -15M | -31M | -40M | -24M | -7M |
| Net Income | -16M | -32M | -39M | -24M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.11
-15.38% today
1Y Change
-8.33%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sernova Corp. (SEOVF) is a Healthcare stock with a market cap of $60.00M and listed on OTC. The stock last traded around $0.11 and down 8.3% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +52.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +52.1%, free cash flow +42.3% with operating margin 0.0% and ROIC 152.4%. Stock Foundry combines SEOVF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SEOVF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SEOVF Max Drawdown
-43.75%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SEOVF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$7.0M
+71.5% YoY
Free Cash Flow
-$6.9M
+53.5% YoY
Revenue Growth
+0.0%
EPS Growth
+52.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -343K | 0 | -446K | -440K | -267K |
| Operating Income | -15M | -32M | -41M | -25M | -7M |
| EBITDA | -15M | -31M | -40M | -24M | -7M |
| Net Income | -16M | -32M | -39M | -24M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 265K | 6M | 9M | 4M | 28M |
| Total Assets | 764K | 8M | 22M | 52M | 30M |
| Total Liabilities | 26M | 20M | 10M | 5M | 2M |
| Shareholder Equity | -25M | -13M | 13M | 48M | 28M |
| Total Debt | 17M | 570K | 136K | 276K | 393K |
| Net Debt | 17M | -5M | -9M | -4M | -27M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
+52.5% YoY
Capital Expenditures
17K
+94.8% YoY
Free Cash Flow
7M
+53.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
51.7%
Debt / Equity
-0.69x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.